Table 2. Association of serum level of miR-409-3p with NMIBC risk.

Level	Cases, N (%)	Controls, N (%)	OR* (95% CI)	P-value	P heterogeneity
Discovery
>2.4	38 (44.19)	48 (55.81)	1 (reference)
0.46-2.4	39 (45.35)	47 (54.65)	1.09 (0.58–2.05)	0.785
≤0.46	54 (62.07)	33 (37.93)	2.32 (1.20–4.49)	0.012
P for trend				0.013
Validation
>2.4	36 (40.91)	52 (59.09)	1 (reference)
0.46-2.4	40 (49.38)	41 (50.62)	1.46 (0.78–2.45)	0.238
≤0.46	46 (58.97)	32 (41.03)	2.19 (1.14–4.22)	0.019
P for trend				0.019
Combined
>2.4	74 (42.29)	101 (57.71)	1 (reference)
0.46-2.4	87 (54.04)	74 (45.96)	1.30 (0.84–2.03)	0.242	0.520
≤0.46	83 (58.87)	58 (41.13)	2.21 (1.40–3.50)	7.19×10–4	0.905
P for trend				7.22×10–4

Significant P-values in bold font.

^*Adjusted by age, sex, smoking status and race.